Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences

References

• Thomas MR, Waxmonsky JA, Gabow PA, et al. Prevalence of psychiatric disorders and costs of care among adult enrollees in a medicaid HMO. Psychiatr Serv 2005;56:1394-401
   PubMed Web of Science ®Google Scholar
• Haro JM, Palacín C, Vilagut G, et al. Grupo ESEMeD-España. Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain. study Med Clin (Barc) 2006;126:445-51
   Google Scholar
• Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87-98
   PubMed Web of Science ®Google Scholar
• Crisp R. Depression and occupational disability in five diagnostic groups: a review of recent research. Disabil Rehabil 2007;29:267-79
   PubMed Web of Science ®Google Scholar
• Sobocki P, Lekander I, Borgstrom F, et al. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 2007;22:146-52
   PubMed Web of Science ®Google Scholar
• Shvartzman P, Weiner Z, Vardy D, et al. Health services utilization by depressive patients identified by the MINI questionnaire in a primary care setting. Scand J Prim Health Care 2005;23:18-25
   PubMed Web of Science ®Google Scholar
• Sicras Mainar A, Navarro Artieda R, Rejas Gutiérrez J, et al. Comorbilidad y coste ambulatorio asociado a los pacientes con trastornos depresivos en un ámbito poblacional. Farm Hosp 2007;31:101-5
   PubMedGoogle Scholar
• Keller MB. Past, present and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003;289:3152-60
   PubMed Web of Science ®Google Scholar
• Zimmernan M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry 2006;163:148-50
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline 23. London: NICE, 2004. Amended, 2006
   Google Scholar
• American Psychiatric Association Practice Guidelines. Treatment of Patients with Major Depressive Disorder, 2nd Edn. April 2000
   Google Scholar
• Fernández A, Haro JM, Martínez-Aloso M, et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry 2007;190:172-3
   PubMed Web of Science ®Google Scholar
• Anon. El Mercado Farmacéutico. IMS Health, April 2009
   Google Scholar
• Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734-50
   PubMed Web of Science ®Google Scholar
• Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;2:CD006532
   PubMed Web of Science ®Google Scholar
• Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259:172-85
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-95
   PubMed Web of Science ®Google Scholar
• Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-41
   PubMed Web of Science ®Google Scholar
• Chenu F, Batten LA, Zernig G, et al. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry 2009;70:958-66
   PubMed Web of Science ®Google Scholar
• Anon. Guidelines for ATC Classification. Oslo: Nordic Collaborating Centre for Drug Statistics Methodology, 1991
   Google Scholar
• Lamberts H, Wood M, Hofmans-Okkes IM (eds). The International Classification of Primary Care in the European Community. With a Multi-Language Layer. Oxford: Oxford University Press, 1993
   Google Scholar
• Conde V, Franch JL. Escalas de evaluación comportamental para la cuantificación de la sintomatología psicopatológica en los trastornos angustiosos y depresivos. Editorial: Departamento de psicología médica y de psiquiatría del Hospital Clínico de la Facultad de Medicina de Valladolid, 1984
   Google Scholar
• Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, et al. Clinical validity of a population database definition of remission in patients with major depression. BMC Public Health 2010;10:64
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Weiner JP, Starfield BH, Steinwachs DM, et al. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991;29:452-72
   PubMed Web of Science ®Google Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200
   PubMed Web of Science ®Google Scholar
• Sackett D, Rosenberg W, Gray J, et al. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312:71-2
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, et al. Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional. Gac Sanit 2010;24:13-19
   PubMed Web of Science ®Google Scholar
• Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009;166:599-607
   PubMed Web of Science ®Google Scholar
• Wade AG, Saragoussi D, Despiégel N, et al. Healthcare expenditure in severely depressed patients treated with escitalopram generic SSRIs or venlafaxine in the UK. Curr Med Res Opin 2010;26:1161-70
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, et al. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007;22:107-15
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
   PubMed Web of Science ®Google Scholar